Despite recent settlements, bankruptcies, and verdicts, opioid litigation is far from winding down. In February, the Providence County Superior Court in Rhode Island denied three motions for summary judgment filed by the remaining defendants, including Teva USA and Cephalon, concluding in part that the evidence overwhelmingly showed the promotion of off-label use of fentanyl drugs. On March 21, the Rhode Island attorney general announced settlements with Teva and Allergan for payment of $28.5 million and provision of $78.5 million in medication to treat opioid addiction. A Georgia case iwas brought by families seeking compensation under the Georgia Drug Dealer Liability Act and was set to be the first state court trial brought by private plaintiffs, although it has been continued until later in 2022. Several settlements have been reached in the opioid case brought by Florida Attorney General Ashley Moody, including a $65M deal in January with Endo Pharmaceuticals, while litigation continues against drug manufacturers and sellers, including Walgreens.